drug · antibody
ravulizumab LA
Marketedupdated 5mo agoby Alexion Pharmaceuticals Inc🔗 ChEMBL
Approvedannual revenue · 2024–2024peak $3.9B
community read0 votes
🐶 often sniffed alongside
top 1Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for hemolytic-uremic syndrome and paroxysmal nocturnal hemoglobinuria and 11 investigational indications.
targets
Complement C5
all catalysts(0)
nothing on the calendar yet
Trials studying ravulizumab LA
- —Real-life Treatment Outcomes of Ravulizumab in PNH
- —Ravulizumab Outcomes in Polish Patients With aHUS
- phase3Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
- phase3ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
- phase3Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
- —Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
- —Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria
- phase3A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
News(5)
- AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowAstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.biospace · 1mo ago
- AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowAstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.biospace · 1mo ago
- FDA scientists question Capricor data; Legend CEO steps downCapricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…biopharma_dive · 2mo ago
- AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failureAstraZeneca remains "very much on track" to hit its 2030 goal of reaching $80 billion in revenue despite the recent late-stage failure of Wainua in ATTR-cardiomyopathy, CEO Pascal Soriot said durin…biospace · 2mo ago
- Updated: AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare diseaseAstraZeneca said Monday that a key late-stage trial of its Claudin 18.2-targeting ADC in stomach cancer had succeeded, albeit with a caveat — but another Phase 3 trial of Ultomiris yielded subpar r…endpoints · 2mo ago
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that